NuCana plc (NASDAQ:NCNA) Short Interest Update

NuCana plc (NASDAQ:NCNA) saw a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 17,700 shares, a drop of 66.9% from the January 31st total of 53,500 shares. Based on an average trading volume of 123,500 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.5% of the company’s shares are short sold.

Hedge Funds Weigh In On NuCana

A number of hedge funds have recently bought and sold shares of NCNA. Schonfeld Strategic Advisors LLC bought a new stake in NuCana during the fourth quarter valued at $54,000. Virtu Financial LLC acquired a new position in shares of NuCana in the 4th quarter valued at about $48,000. Citadel Advisors LLC bought a new stake in shares of NuCana during the 4th quarter valued at about $30,000. Finally, Two Sigma Securities LLC acquired a new stake in NuCana during the fourth quarter worth approximately $25,000. Institutional investors own 44.00% of the company’s stock.

NuCana Price Performance

NuCana stock opened at $0.93 on Friday. The stock’s 50 day moving average is $1.10 and its 200 day moving average is $2.12. NuCana has a one year low of $0.85 and a one year high of $19.41. The firm has a market cap of $2.45 million, a P/E ratio of -0.09 and a beta of 0.96.

NuCana (NASDAQ:NCNA) last issued its quarterly earnings results on Monday, November 25th. The company reported ($2.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.49) by $1.21. Equities analysts anticipate that NuCana will post -13.42 earnings per share for the current fiscal year.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.